BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Zhang H, Chen L, Chen Y, Chen L, Ren H, Hu H. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2015;39:80-92. [DOI: 10.1016/j.clinre.2014.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol C, Piratvisuth T. Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. Clin Mol Hepatol 2019;25:366-73. [PMID: 31309773 DOI: 10.3350/cmh.2018.0111] [Reference Citation Analysis]
2 Tavakolpour S, Alavian SM, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. Hepat Mon 2016;16:e35810. [PMID: 27257429 DOI: 10.5812/hepatmon.35810] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
3 Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 2016;16:917-26. [PMID: 27088278 DOI: 10.1080/14712598.2016.1177017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
4 Cam S, Yoruk MA. Alteration in Hepatitis B Serology in Children Receiving Chemotherapy. Viral Immunol 2020;33:628-33. [PMID: 33090085 DOI: 10.1089/vim.2020.0194] [Reference Citation Analysis]
5 Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol 2016;4:143-50. [PMID: 27350944 DOI: 10.14218/JCTH.2016.00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
7 Zhang MY, Zhu GQ, Zheng JN, Cheng Z, Van Poucke S, Shi KQ, Huang HH, Chen FY, Zheng MH. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Expert Rev Anti Infect Ther 2017;15:503-13. [PMID: 28317397 DOI: 10.1080/14787210.2017.1309291] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
8 Wu YT, Li X, Liu ZL, Xu Z, Dai W, Zhang K, Wu JS, Arshad B, Wu KN, Kong LQ. Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. PLoS One 2017;12:e0179680. [PMID: 28640902 DOI: 10.1371/journal.pone.0179680] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
9 Terrault N. Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough? Clinical Liver Disease. 2015;5:43-46. [PMID: 31040947 DOI: 10.1002/cld.447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Su J, Long L, Zou K. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Clin Rheumatol 2018;37:3201-14. [PMID: 29637482 DOI: 10.1007/s10067-018-4096-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y, Zhang XH, Gao YH, Niu ZX, Feng R, Wang W, Peng JW, Li XL, Ouyang XN, Wu CP, Zhang WJ, Zeng Y, Xiao Z, Liang YM, Zhuang YZ, Wang JS, Sun ZM, Bai H, Cui TJ, Feng JF. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chin Med J (Engl) 2018;131:1767-75. [PMID: 30058572 DOI: 10.4103/0366-6999.237401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Xu Z, Dai W, Wu YT, Arshad B, Li X, Wu H, Chen HR, Wu KN, Kong LQ. Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis. Eur J Cancer Care (Engl) 2018;27:e12799. [PMID: 29265535 DOI: 10.1111/ecc.12799] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 He LY, Wang YL, Tian X, Chen WQ. The association of hepatitis B virus screening and antiviral prophylaxis with adverse liver outcomes in Chinese cancer patients undergoing chemotherapy: A retrospective study. Medicine (Baltimore) 2020;99:e19647. [PMID: 32243396 DOI: 10.1097/MD.0000000000019647] [Reference Citation Analysis]
14 Yu S, Luo H, Pan M, Luis AP, Xiong Z, Shuai P, Zhang Z. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016;38:1035-43. [PMID: 27450506 DOI: 10.1007/s11096-016-0358-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
15 Ciccullo A, Ponziani FR, Maiolo E, Pallavicini F, Pompili M. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection 2019;47:313-6. [PMID: 30368733 DOI: 10.1007/s15010-018-1242-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci 2021;112:1943-54. [PMID: 33576088 DOI: 10.1111/cas.14846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]